Life after death: RIP1 and RIP3 move beyond necroptosis

por Berger, SB, Bertin, J, Gough, PJ
Publicado 2016

Litigating reproductive and developmental health in the aftermath of UAW versus Johnson Controls.

por Clauss, C A, Berzon, M, Bertin, J
Publicado 1993

Drilling into RIP1 biology: what compounds are in your toolkit?

por Berger, S B, Bertin, J, Gough, P J
Publicado 2015

Avian diseases which affect egg production and quality

por Roberts, J.R., Souillard, R., Bertin, J.
Publicado 2011

Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death

por Moriwaki, K, Bertin, J, Gough, P J, Orlowski, G M, Chan, F KM
Publicado 2015

Absence of RIPK3 predicts necroptosis resistance in malignant melanoma

por Geserick, P, Wang, J, Schilling, R, Horn, S, Harris, P A, Bertin, J, Gough, P J, Feoktistova, M, Leverkus, M
Publicado 2015

Identification of Blau Syndrome disease signatures

por Foley, KP, Wang, L, Cooper, D, Magid-Slav, M, Lipshutz, D, Connor, J, Miller, M, Votta, B, Gough, P, Valencia, X, Wouters, CH, Rosé, CD, Bertin, J
Publicado 2011

Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase

por Berger, SB, Harris, P, Nagilla, R, Kasparcova, V, Hoffman, S, Swift, B, Dare, L, Schaeffer, M, Capriotti, C, Ouellette, M, King, BW, Wisnoski, D, Cox, J, Reilly, M, Marquis, RW, Bertin, J, Gough, PJ
Publicado 2015

OR3-001 – RIP2 kinase is activated in Blau Syndrome and IBD

por Foley, KP, Desai, B, Vossenkämper, A, Reilly, MA, Biancheri, P, Wang, L, Lipshutz, DB, Connor, J, Miller, M, Haile, PA, Casillas, LN, Votta, BJ, Gough, PJ, MacDonald, TT, Wouters, CH, Rosé, CD, Bertin, J
Publicado 2013